Clopidogrel pathway

被引：194
作者：
Sangkuhl, Katrin
Klein, Teri E. [1 ]
Altman, Russ B. [2 ]
机构：
[1] Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
来源：
PHARMACOGENETICS AND GENOMICS | 2010年 / 20卷 / 07期
关键词：
clopidogrel; CYP2C19; CYP2C19*2; 2-oxo-clopidogrel; PharmGKB; pharmacokinetics; platelet aggregation; thienopyridine; OF-FUNCTION POLYMORPHISM; ACUTE CORONARY SYNDROME; PROTON PUMP INHIBITORS; DRUG-DRUG INTERACTION; CYTOCHROME-P450; 3A; ATORVASTATIN; RESPONSIVENESS; PHARMACOKINETICS; ASSOCIATION; METABOLISM;
D O I：
10.1097/FPC.0b013e3283385420
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：463 / 465
页数：3
相关论文
共 30 条
[1]   Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].
Brandt, J. T. ;
Close, S. L. ;
Iturria, S. J. ;
Payne, C. D. ;
Farid, N. A. ;
Ernest, C. S., II ;
Lachno, D. R. ;
Salazar, D. ;
Winters, K. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436
[2]  
Caplain H, 1999, SEMIN THROMB HEMOST, V25, P25
[3]   The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J].
Clarke, TA ;
Waskell, LA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :53-59
[4]   Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J].
Collet, Jean-Philippe ;
Hulot, Jean-Sebastien ;
Pena, Anna ;
Villard, Eric ;
Esteve, Jean-Baptiste ;
Silvain, Johanne ;
Payot, Laurent ;
Brugier, Delphine ;
Cayla, Guillaume ;
Beygui, Farzin ;
Bensimon, Gilbert ;
Funck-Brentano, Christian ;
Montalescot, Gilles .
LANCET, 2009, 373 (9660) :309-317
[5]   Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study [J].
Cuisset, Thomas ;
Frere, Corinne ;
Quilici, Jacques ;
Poyet, Raphael ;
Gaborit, Benedicte ;
Bali, Laurent ;
Brissy, Olivier ;
Morange, Pierre-Emmanuel ;
Alessi, Marie-Christine ;
Bonnet, Jean-Louis .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) :1149-1153
[6]   Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J].
Farid, N. A. ;
Payne, C. D. ;
Small, D. S. ;
Winters, K. J. ;
Ernest, C. S., II ;
Brandt, J. T. ;
Darstein, C. ;
Jakubowski, J. A. ;
Salazar, D. E. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :735-741
[7]   Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness [J].
Fontana, Pierre ;
Senouf, David ;
Mach, Francois .
THROMBOSIS RESEARCH, 2008, 121 (04) :463-468
[8]   CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [J].
Geisler, Tobias ;
Schaeffeler, Elke ;
Dippon, Juergen ;
Winter, Stefan ;
Buse, Verena ;
Bischofs, Christian ;
Zuern, Christine ;
Moerike, Klaus ;
Gawaz, Meinrad ;
Schwab, Matthias .
PHARMACOGENOMICS, 2008, 9 (09) :1251-1259
[9]   Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [J].
Gilard, Martine ;
Arnaud, Bertrand ;
Cornily, Jean-Christophe ;
Le Gal, Gregoire ;
Lacut, Karine ;
Le Calvez, Genevive ;
Mansourati, Jacques ;
Mottier, Dominique ;
Abgrall, Jean-Francois ;
Boschat, Jacques .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (03) :256-260
[10]   Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients [J].
Giusti, Betti ;
Gori, Anna Maria ;
Marcucci, Rossella ;
Saracini, Claudia ;
Sestini, Ilaria ;
Paniccia, Rita ;
Valente, Serafina ;
Antoniucci, Davide ;
Abbate, Rosanna ;
Gensini, Gian Franco .
PHARMACOGENETICS AND GENOMICS, 2007, 17 (12) :1057-1064
123